Module 5: Drug discovery and Development as a process Flashcards

1
Q

anything within a living organism to which some other entity (like an endogenous ligand or a drug) is directed and/or binds, resulting in a change in its behavior or function.

Native protein in the body whose activity is modified by a drug resulting in a specific effect, which may be a desirable therapeutic effect or an unwanted adverse effect.

A

Biological target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

often referred to as a drug target

A

Biological target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The most common drug targets:

A

Proteins
Ion channels
nucleic acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Most common biological targets:

A

Proteins
* G protein-coupled receptors (target of 50% of drugs)
* Enzymes (especially protein kinases, proteases, esterases, and phosphatases)
Ion channels
* ligand-gated ion channels
* voltage-gated ion channels
* nuclear hormone receptors
* structural proteins such as tubulin
* membrane transport proteins
Nucleic acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Decision to focus on finding an agent with a particular biological action that is anticipated to have therapeutic utility.

A

Target Identification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

It is influenced by a complex balance of scientific, medical and strategic considerations.

A

Target characterization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Characterization of the molecular mechanisms
addressed by the target.

A good target should be _____

A
  • efficacious,
  • safe,
  • meet clinical and commercial requirements and be ‘druggable’
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what makes a ‘good’ target?

A
  1. The target has a confirmed role in the pathophysiology of a disease and/or is disease modifying
  2. Target expression is not evenly distributed throughout the body.
  3. The target’s 3D-structure is available to assess druggability.
  4. The target is easily ‘assayable’ enabling high-throughput screening.
  5. The target possesses a promising toxicity profile, potential adverse effects can be predicted using phenotypic data
  6. The proposed target has a favorable intellectual property (IP) status. (relevant for pharma companies)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Common Approaches in identifying a target:

A

Data mining using bioinformatics
Genetic association
Expression profile
Pathway and phenotypic analysis
Functional screening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Identifying, selecting and prioritizing potential disease targets

A

Data mining using bioinformatics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Genetic polymorphism and connection with the disease

A

Genetic association

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Changes in mRNA/protein levels

A

Expression profile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

In vitro cell-based mechanistic studies

A

Pathway and phenotypic analysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

knock down, knockout or using target specific tools.

A

Functional screening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Tools for Target Identification & Validation:

A
  • Disease association (genetics and expression changes)
  • Bioactive molecules Cell based models
  • Protein interactions (pull-down assays, yeast 2 hybrid)
  • Analysis of signaling pathways
  • Functional analysis (overexpression, transgenics, antisense RNA, gene variants)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Two target identification strategies:

A

Target deconvolution
Target discovery

17
Q

In this scenario you begin with a drug that appears efficacious and the target is identified retrospectively.

A

Target deconvolution

18
Q

This approach works on the concept that ‘if you want a new drug you must find a new target’, once a target is identified compound libraries are then screened to find a drug that binds to the target and elicits the desired effect.

A

Target discovery

19
Q

The phenotypic approach to drug discovery falls within the realm of _____, and involves exposing cells, isolated tissues, or animal models, to small molecules to determine whether a specific candidate molecule exerts the desired effect – which is observed by a change in phenotype.

A

target deconvolution

20
Q
  • The phenotypic approach goes
    beyond individual proteins or nucleic
    acids and involves the study of entire
    signaling pathways.
  • The drug’s effect is determined before
    the specific biological (drug) target
    that underlies the observed
    phenotypic response is identified
A

N/A

21
Q

Advantages and challenges of phenotypic drug
discovery:

A
  • The greatest advantage of phenotypic
    approaches have over target-based is their
    ability to demonstrate the efficacy of a drug in
    the context of a cellular environment.
  • The drug is acting on the target in its ‘normal’
    biological context, rather than on a purified
    target in a biochemical screen.
22
Q
  • In target-based drug discovery, biological (drug) targets are already established (or ‘discovered’) before lead discovery starts – hence __________ is the cornerstone of target-based screening.
  • The target’s role in a disease process is known, this target is then used to create relevant systems-based assays, and vast compound libraries are screened in search of a ‘hit’ – a candidate drug.
A

Target discovery